DCPH - Deciphera Pharmaceuticals, Inc.
IEX Last Trade
12.94
0.120 0.927%
Share volume: 346,158
Last Updated: Tue 08 Aug 2023 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$12.82
0.12
0.94%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
| Report Date | 2022-05-04 | 2022-08-04 | 2022-11-03 | 2023-02-07 | 2023-05-03 | 2023-08-09 | 2023-10-30 | |
| Assets | ||||||||
| Total Assets | 385.464 M | 507.037 M | 475.952 M | 454.039 M | 549.019 M | 509.618 M | 497.836 M | |
| Current Assets | 319.835 M | 448.531 M | 420.879 M | 392.958 M | 476.159 M | 405.050 M | 417.576 M | |
| Inventories | 19.627 M | 20.889 M | 19.129 M | 20.561 M | 25.528 M | 25.343 M | 27.105 M | |
| Other Current Assets | 20.504 M | 17.944 M | 13.895 M | 25.482 M | 29.559 M | 27.767 M | 23.847 M | |
| Short Term Investments | 20.504 M | 17.944 M | 13.895 M | 25.482 M | 29.559 M | 27.767 M | 23.847 M | |
| Total Receivables | 23.151 M | 25.851 M | 23.278 M | 22.429 M | 22.439 M | 23.200 M | 27.549 M | |
| Current Cash | 256.553 M | 383.847 M | 364.577 M | 324.486 M | 398.633 M | 328.740 M | 339.075 M | |
| Total Non-current Assets | 65.629 M | 58.506 M | 55.073 M | 61.081 M | 72.860 M | 104.568 M | 80.260 M | |
| Property Plant Equipment | 7.821 M | 7.353 M | 7.152 M | 6.707 M | 6.511 M | 6.213 M | 5.864 M | |
| Other Assets | 35.846 M | 38.676 M | 37.639 M | 36.547 M | 35.445 M | 34.333 M | 33.209 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 385.464 M | 507.037 M | 475.952 M | 454.039 M | 549.019 M | 509.618 M | 497.836 M | |
| Total liabilities | 113.899 M | 102.026 M | 102.176 M | 112.348 M | 108.935 M | 105.188 M | 116.166 M | |
| Total current liabilities | 86.670 M | 74.545 M | 75.468 M | 86.469 M | 83.913 M | 81.034 M | 92.894 M | |
| Accounts Payable | 17.801 M | 16.229 M | 12.800 M | 18.612 M | 19.670 M | 18.211 M | 21.453 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 2.931 M | 3.102 M | 3.170 M | 3.235 M | 3.301 M | 3.368 M | 3.436 M | |
| Long term debt | 27.229 M | 27.481 M | 26.708 M | 25.879 M | 25.022 M | 24.154 M | 23.272 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 271.565 M | 405.011 M | 373.776 M | 341.691 M | 440.084 M | 404.430 M | 381.670 M | |
| Common stock | 58.616 M | 72.133 M | 78.207 M | 93.044 M | 82.677 M | 85.020 M | 85.789 M | |
| Retained earnings | -1.101 B | -1.144 B | -1.187 B | -1.233 B | -1.283 B | -1.332 B | -1.381 B |